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Introduction {#jdi12865-sec-0005}
============

Older people with diabetes mellitus, have an approximately 1.5‐ to twofold‐increased risk of cognitive impairment and dementia[1](#jdi12865-bib-0001){ref-type="ref"}. Given the high prevalence of diabetes mellitus in older people, the identification of potentially modifiable risk factors of cognitive decline in this high‐risk group is important. The mechanisms underlying progressive cognitive deficits are likely to be multifactorial, as diabetes mellitus is associated with cardiovascular disease, white matter brain changes and Alzheimer\'s disease[2](#jdi12865-bib-0002){ref-type="ref"}.

Furthermore, hypoglycemia is associated with an increased risk of cognitive decline and dementia in patients with diabetes mellitus. In a cross‐sectional study of \>1,000 patients, a self‐reported history of severe hypoglycemia was significantly associated with worse later‐life cognitive function independent of initial cognitive function[3](#jdi12865-bib-0003){ref-type="ref"}. Another prospective study of \>16,000 older adults with diabetes mellitus also suggested that the accumulation of severe hypoglycemic events over the preceding 20 years was significantly associated with a greater risk of dementia[4](#jdi12865-bib-0004){ref-type="ref"}. The effect of repeated hypoglycemia episodes on the development of cognitive decline is due to neuronal loss as a result of an impaired fuel supply[5](#jdi12865-bib-0005){ref-type="ref"}.

Dyslipidemia has been shown to have a strong additive influence on the cognitive performance of patients with Alzheimer\'s disease[6](#jdi12865-bib-0006){ref-type="ref"}. Diabetes mellitus is related with microvascular complications, including nephropathy. Kidney dysfunction has been found to be associated with more rapid decline in performance in domains of attention and processing speed[7](#jdi12865-bib-0007){ref-type="ref"}. Diabetes mellitus is also associated with clinical stroke, white matter disease and asymptomatic cerebral infarctions, which could affect cognitive functions in older people with diabetes mellitus[8](#jdi12865-bib-0008){ref-type="ref"}.

Therefore, we explored clinical factors associated with global cognitive deficit and specific cognitive domains at the 27‐month follow up among older people with diabetes mellitus.

Methods {#jdi12865-sec-0006}
=======

The sample was drawn from existing data of a randomized trial of vitamin B~12~ supplementation, who were administered the cognitive functional tests at baseline and at 9‐month intervals until month 27[9](#jdi12865-bib-0009){ref-type="ref"}. This trial showed no significant effect of vitamin B~12~ supplementation on cognitive decline. Hence, we carried out the secondary analysis to identify risk factors associated with cognitive function in this intervention trial and adjusted for treatment assignment.

A total of 271 participants with type 2 diabetes mellitus aged \>70 years were recruited in Hong Kong from August 2011 to September 2013. Details of sampling procedures and collection methods of the original sample have been described previously[9](#jdi12865-bib-0009){ref-type="ref"}. In brief, all the participants with borderline low vitamin B~12~ (150--300 pmol/L) were screened in the research clinic at the Prince of Wales Hospital and seven family medicine/general outpatient clinics in the New Territories East cluster in Hong Kong. Exclusion criteria included: (i) individuals with a clinical diagnosis of dementia, peripheral neuropathy, anemia, disabling stroke, renal failure or clinical depression; (ii) individuals taking vitamin B~12~ supplementation or centrally‐acting medications; and (iii) individuals without a family member who could reliably inform on cognitive functioning. At entry, all study participants attended the research clinic for extensive physical and cognitive function assessment, and every 9 months they came back to attend these examinations until 27 months. A total of 234 participants (86.4%) completed the follow up.

After having obtained written consent from participants, all of the participants had the following measurements:

Blood samples were taken after an overnight fast. The blood was analyzed for glycosylated hemoglobin, creatinine and low‐density lipoprotein cholesterol, total cholesterol, high‐density lipoprotein cholesterol (HDL‐C), non‐HDL‐C and triglycerides. Apolipoprotein E genotyping was also analyzed from ethylenediaminetetraacetic acid blood samples.All basic information of participants was collected at baseline by questionnaires that included: demographic information, education years, smoking status, medical diagnoses and medication. Additionally, a history of hypoglycemia was assessed by self‐report (frequency in recent 1 month), and duration of diabetes mellitus was recorded.Neuropsychological tests. (i) Chinese Mini‐Mental State Examination -- the version has been validated suitably for individuals in Hong Kong and the total score is 30. (ii) Clinical Dementia Rating scale (CDR) -- a numeric scale used to rate the severity of symptoms of dementia and reflecting a clinical impression of global cognitive and functional impairment. It is a well‐structured interview‐based test. Besides an interview with a patient, a caregiver who has regular personal contact with the patient also completes the CDR rating ranges from 0 (normal) to 3 (severe dementia). A CDR score of 0 indicates normal cognition, 0.5 indicates 'questionable dementia' or mild cognitive impairment and a score of ≥1 might indicate 'clinical dementia.' All the participants were divided into two groups based on their CDR global scores at baseline, and participants with CDR global scores of 0 were defined as the cognitively normal group, whereas the participants with CDR global scores of ≥0.5 were the mild cognitive impairment group. Cognitive decline was defined as any increase in CDR global score at 27‐month follow up. (iii) Neuropsychological Test Battery (NTB) -- the cognitive test battery was chosen for specific assessments[10](#jdi12865-bib-0010){ref-type="ref"}. The tests included: Controlled Oral Word Association Test and the Category Fluency Test (to name animals, vegetables and fruits in 1 min each), International Shopping List Test, 'Detection' (a test of simple reaction time) and 'Identification' (a choice reaction time test) and Continuous Paired Associates Learning. The selected assessments were carried out face‐to‐face by well‐trained research assistant using a touch‐screen portable computer. From these tests, composite cognitive function scores were formed to represent three cognitive domains (executive function, psychomotor speed and memory), raw scores from the cognitive tests were converted to *z*‐scores; (value − mean at baseline)/standard deviation at baseline was used to compute the *z*‐scores, with higher *z*‐scores indicating better performance. (iv) Geriatric Depression Scale -- it contains 15 items with a score of ≥8 indicating depression. The version has been validated in the Hong Kong population.

Statistical analysis {#jdi12865-sec-0007}
--------------------

The primary outcome was change in CDR global score, and the secondary outcomes were NTB domain *z*‐scores. Continuous variables were presented as the mean (standard deviation) and prevalence (percentage), as appropriate, then compared by using independent samples *t*‐test or the χ^2^‐test. Binomial logistic regression was carried out to examine predictors for CDR changes. All clinically plausible variables with *P* \< 0.20 in the respective bivariate analyses were considered for the models. As the current study was based on a previous vitamin B~12~ supplementation randomized placebo trial, the effect of treatment assignment would be taken into consideration in all models.

The partial correlation coefficient was used to identify the biomarkers related to *z*‐scores of domain performance in NTB at month 27 with correction for age and sex. Significant correlations (*P* \< 0.05) were reported. Then, the linear regression model was carried out to investigate the association between significant factors and *z*‐score in the NTB domain after adjustment for age, sex, education level, treatment assignment and corresponding baseline *z*‐score. All the analysis were carried out with SPSS software (IBM SPSS Statistics version 24.0; IBM Corporation, Armonk, NY, USA).

Results {#jdi12865-sec-0008}
=======

Table [1](#jdi12865-tbl-0001){ref-type="table"} summarizes the baseline characteristics of the participants. A total of 271 older people aged 69--85 years were included. Majority of participants (77.49%) had diabetes mellitus for \>10 years. More than half of the participants (56%) had a CDR score of 0 at baseline. The cognitive impaired group had received less education and had a higher proportion of women, stroke patients and smokers than the normal cognition group.

###### 

Clinical characteristics of all trial participants at baseline

                                               Normal (*n* = 152)   MCI (*n* = 119)   *P*              
  -------------------------------------------- -------------------- ----------------- -------- ------- ---------
  Age (years)                                  74.91                3.88              75.55    4.23    0.196
  Education (years)                            6.98                 4.62              4.13     3.81    \<0.001
  HbA1c (%)                                    7.1                  0.9               7.2      0.9     0.485
  Creatinine (μmol/L)                          91.63                25.14             87.44    24.83   0.172
  HDL (mmol/L)                                 1.30                 0.33              1.28     0.31    0.507
  LDL (mmol/L)                                 2.33                 0.69              2.32     0.67    0.937
  Total‐C (mmol/L)                             4.24                 0.86              4.25     0.74    0.961
  Non‐HDL (mmol/L)                             2.91                 0.82              2.97     0.76    0.598
  Triglyceride (g/L)                           1.37                 0.87              1.45     0.76    0.456
  Hemoglobin (g/dL)                            13.28                1.16              12.90    1.39    0.016
  Urine albu:creat                             14.92                34.92             15.23    26.88   0.949
  MCV (fL)                                     90.33                7.16              89.41    7.55    0.316
  MMSE (max 30)                                27.14                2.28              22.89    3.51    \<0.001
  GDS (max 15)                                 2.91                 2.15              3.99     2.38    \<0.001
  NTB[†](#jdi12865-note-0001){ref-type="fn"}                                                           
  Executive function                           0.28                 0.83              --0.39   0.73    \<0.001
  Psychomotor speed                            0.16                 0.89              --0.10   0.83    0.023
  Memory                                       0.23                 0.79              --0.28   0.73    \<0.001

                                                 *n*   \%     *n*   \%     
  ---------------------------------------------- ----- ------ ----- ------ ---------
  Hypertension                                   129   84.9   104   87.4   0.552
  Stroke                                         6     3.9    12    10.1   0.044
  Smoker                                         8     6      10    10.5   0.090
  APOE4[‡](#jdi12865-note-0001){ref-type="fn"}   19    12.5   19    16.1   0.358
  APOE3/3                                        99    65.1   79    66.9   0.671
  Drug use                                                                 
  Aspirin                                        32    21.1   35    29.4   0.113
  Insulin                                        24    15.8   15    12.6   0.459
  Metformin                                      125   82.2   102   85.7   0.441
  Statin                                         76    50     70    58.8   0.148
  ACEI/ARB                                       116   76.8   92    77.3   0.920
  Female                                         46    30.2   67    56.3   \<0.001
  Supplement group                               76    50     61    51.3   0.903
  DM duration ≥10 years                          114   75     96    80.7   0.151
  Hypoglycemia                                   25    16.4   14    11.8   0.280
  Hospital admission for hypoglycemia            3     2.0    6     5.0    0.159

^†^The *z*‐scores as compared with the mean of all participants; higher scores indicating better performance. ^‡^One copy. ACEI, angiotensin‐converting enzyme inhibitor; albu:creat, albumin (g) and creatinine (μmol/L) ratio; ApoE, apolipoprotein E; ARB, angiotensin receptor blocker; DM, diabetes mellitus; GDS, Geriatric Depression Scale; HbA1c, glycosylated hemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; max, maximum; MCI, mild cognitive impaired (Clinical Dementia Rating scale score 0.5); MCV, mean corpuscular volume; MMSE, Mini‐Mental State Examination; Non‐HDL, non‐high‐density lipoprotein; NTB, Neuropsychological Test Battery; SD, standard deviation; Total‐C, total cholesterol.
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A total of 41 (15%) participants had an increase in the CDR global score at month 27. Among these participants, five had cognitive impairment at baseline. In contrast, among non‐decliners, 16 participants\' CDR global score decreased (improved) at month 27. Table [2](#jdi12865-tbl-0002){ref-type="table"} compares clinical characteristics among decliners and non‐decliners. Variables associated with an increase in CDR global score in the univariate analysis were being male, and having higher serum creatinine and a higher Mini‐Mental State Examination score. Use of statins, angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker, insulin, metformin, duration of diabetes mellitus and hypoglycemia frequency were not significantly different between the two groups.

###### 

Comparisons of cognitive decliners and non‐decliners according to Clinical Dementia Rating scale global score

                                               Decliners (*n* = 41)                            Non‐decliners (*n* = 202)   *P*                                                        
  -------------------------------------------- ----------------------------------------------- --------------------------- ----------------------------------------------- ---------- -------
  Age (years)                                  76.41                                           4.20                        74.93                                           3.98       0.032
  Education (years)                            6.75                                            4.97                        5.89                                            4.41       0.264
  HbA1c, mmol/mol (%)                          78 (7.1)                                        12 (1.1)                    77 (7.1)                                        10 (0.9)   0.593
  Creatinine (μmol/L)                          97.39                                           24.06                       87.74                                           24.95      0.024
  Urine albu:creat                             16.09                                           36.76                       13.88                                           26.64      0.712
  HDL (mmol/L)                                 1.28                                            0.32                        1.30                                            0.32       0.624
  LDL (mmol/L)                                 2.29                                            0.89                        2.33                                            0.64       0.686
  Total‐C (mmol/L)                             4.18                                            1.09                        4.27                                            0.76       0.526
  Non‐HDL (mmol/L)                             2.89                                            1.14                        2.94                                            0.71       0.740
  Triglyceride (g/L)                           1.37                                            0.83                        1.41                                            0.83       0.737
  Hemoglobin (g/dL)                            12.97                                           1.34                        13.17                                           1.25       0.342
  MCV (fL)                                     90.66                                           6.11                        90.06                                           7.67       0.641
  MMSE (max 30)                                26.56                                           2.69                        25.25                                           3.65       0.030
  GDS (max 15)                                 3.00                                            1.73                        3.41                                            2.41       0.301
  NTB[†](#jdi12865-note-0002){ref-type="fn"}                                                                                                                                          
  Executive function                           −0.001                                          0.88                        0.004[§](#jdi12865-note-0002){ref-type="fn"}    0.85       0.768
  Psychomotor speed                            −0.007[¶](#jdi12865-note-0002){ref-type="fn"}   0.89                        0.041[††](#jdi12865-note-0002){ref-type="fn"}   0.88       0.311
  Memory                                       0.029[‡‡](#jdi12865-note-0002){ref-type="fn"}   0.82                        0.002[§§](#jdi12865-note-0002){ref-type="fn"}   0.79       0.809
  Total                                        0.119                                           0.56                        0.06                                            0.64       0.935

                                                 *n*   \%      *n*   \%      
  ---------------------------------------------- ----- ------- ----- ------- -------
  Hypertension                                   37    90.2    170   84.2    0.317
  Stroke                                         3     7.31    13    6.44    0.836
  Smoker                                         2     5.0     16    8.56    0.058
  APOE4[‡](#jdi12865-note-0002){ref-type="fn"}   6     14.63   28    13.93   0.906
  APOE3/3                                        28    68.3    129   64.2    0.615
  Drug use                                                                   
  Aspirin                                        8     19.5    54    26.7    0.334
  Insulin                                        1     2.43    25    12.4    0.177
  Metformin                                      37    90.2    66    32.7    0.204
  Statin                                         20    48.8    111   54.9    0.407
  ACEI/ARB                                       23    56.1    122   60.39   0.609
  Female                                         11    26.8    87    43.1    0.053
  Supplement group                               23    56.1    99    49      0.408
  DM duration ≥10 years                          33    80.5    156   77.2    0.560
  Hypoglycemia                                   8     19.5    30    14.85   0.445
  Hospital admission for hypoglycemia            1     2.4     8     4.0     0.641

^†^The *z*‐scores as compared with the mean of all participants; higher scores indicating better performance. ^‡^One copy. ^§^ *n* = 195 participants; ^¶^ *n* = 36 participants; ^††^ *n* = 181 participants; ^‡‡^ *n* = 39 participants; ^§§^ *n* = 192 participants. ACEI, angiotensin‐converting enzyme inhibitor; albu:creat, albumin (g) and creatinine (μmol/L) ratio; ApoE, apolipoprotein E; ARB, angiotensin receptor blocker; DM, diabetes mellitus; GDS, Geriatric Depression Scale; HbA1c, glycosylated hemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; max, maximum; MCI, mild cognitive impaired (Clinical Dementia Rating scale score 0.5); MCV, mean corpuscular volume; MMSE, Mini‐Mental State Examination; Non‐HDL, non‐high‐density lipoprotein; NTB, Neuropsychological Test Battery; Total‐C, total cholesterol.
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Multiple logistic regression models were used to detect predictors of cognitive decline, and all clinically plausible variables with *P* \< 0.2 in the univariate analyses were included in the model; that is, age, creatinine, smoking status, insulin treatment and sex (shown in Table [2](#jdi12865-tbl-0002){ref-type="table"}). Mini‐Mental State Examination was not included in the model, as its strong correlation with cognitive decline without dementia and randomization was included in model. None of these factors were significantly associated with cognitive decline.

Partial correlation analysis showed that serum HDL‐C level was associated with executive function at month 27 (correlation coefficient 0.248, *P* \< 0.001). No clinical factors correlated significantly with psychomotor speed and memory (shown in Table [S1](#jdi12865-sup-0001){ref-type="supplementary-material"}). A linear regression model was used to investigate the association between HDL‐C level and executive function at month 27 with correction for age, sex, education years, trial group assignment and baseline executive function. HDL‐C was positively associated with executive function at month 27 (β = 0.359, *P* \< 0.001, 95% confidence interval 0.236--0.483). With further correction for the use of statin, HDL‐C was still significantly associated with executive function at month 27 (β = 0.366, *P* = 0.004, 95% confidence interval 0.116--0.616). On multilevel modeling of executive function at all time‐points, the highest tertile of the HDL‐C group had better executive function than the lowest tertile of the HDL‐C group after adjustment for age, sex, education and trial group assignment (Table [3](#jdi12865-tbl-0003){ref-type="table"}; Figure [1](#jdi12865-fig-0001){ref-type="fig"}). Time did not have an interaction effect on the association of the HDL‐C group with executive function (*P* = 0.963). The clinical characteristics of the participants in the tertiles of serum HDL‐C are shown in Table [4](#jdi12865-tbl-0004){ref-type="table"}. Serum total cholesterol levels and triglyceride were significantly higher, whereas non HDL‐C levels were significantly decreased in the upper tertile of serum HDL‐C. In addition, the upper tertile of serum HDL‐C included a higher proportion of women. There were no significant differences in other clinical characteristics.

###### 

Comparisons of executive function between HDL‐C tertiles at follow up

                    Baseline                                              9‐month follow up                                     18‐month follow up                                      27‐month follow up
  ----------------- ----------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------- -------------------------------------------------------
  Lowest tertile    −0.01 (0.83)                                          −0.01 (0.89)                                          −0.09 (0.80)                                            0.04 (0.87)
  Middle tertile    −0.11 (0.78)                                          −0.10 (0.87)                                          −0.01 (1.02)                                            −0.01 (0.82)
  Highest tertile   0.16[\*](#jdi12865-note-0003){ref-type="fn"} (0.93)   0.18[\*](#jdi12865-note-0003){ref-type="fn"} (0.96)   0.18[\*\*](#jdi12865-note-0003){ref-type="fn"} (0.96)   0.33[\*\*](#jdi12865-note-0003){ref-type="fn"} (1.01)

Data presented as mean (standard deviation) of *z*‐scores. \*,\*\*Significantly different from the lowest tertile, *P* \< 0.05 and *P* \< 0.01, respectively.
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![Comparisons of executive function among high‐density lipoprotein cholesterol tertiles at all time‐points. \*^,^\*\*Significantly different from the lowest tertile, *P* \< 0.05 and *P* \< 0.01, respectively.](JDI-10-139-g001){#jdi12865-fig-0001}

###### 

Clinical characteristics of the participants in the tertiles of serum high‐density lipoprotein cholesterol

                                                 Lowest tertile   Middle tertile   Upper tertile   *P*                     
  ---------------------------------------------- ---------------- ---------------- --------------- ------- ------- ------- -------------------------------------------------
  Age (years)                                    75.40            4.19             75.67           4.01    74.83   4.00    0.445
  Education (years)                              6.77             4.22             5.53            4.98    5.29    4.07    0.067
  HbA1c (%)                                      7.21             1.04             7.04            0.79    7.00    0.94    0.313
  Creatinine (μmol/L)                            97.09            24.69            84.94           23.96   85.65   26.90   0.213
  LDL (mmol/L)                                   2.37             0.72             2.32            0.60    2.27    0.72    0.648
  Total‐C (mmol/L)                               4.09             0.82             4.23            0.77    4.46    0.80    0.013[\*](#jdi12865-note-0004){ref-type="fn"}
  Non‐HDL (mmol/L)                               3.10             0.82             2.97            0.63    2.70    0.85    0.010[\*](#jdi12865-note-0004){ref-type="fn"}
  Triglyceride (g/L)                             1.61             0.81             1.42            1.01    1.11    0.46    \<0.001[\*](#jdi12865-note-0004){ref-type="fn"}
  Hemoglobin (g/dL)                              13.47            1.30             12.82           1.25    13.09   1.21    0.312
  Urine albu:creat                               16.82            32.52            20.65           41.30   8.30    17.62   0.165
  MCV (fL)                                       90.32            6.35             89.08           8.26    90.59   7.35    0.396
  MMSE (max 30)                                  25.99            3.02             24.95           3.78    24.82   3.82    0.059
  GDS (max 15)                                   3.82             2.25             3.23            2.24    3.19    2.32    0.426
  Hypertension                                   82               87.23            70              89.74   56      78.87   0.143
  Stroke                                         8                8.51             5               6.41    2       2.82    0.321
  Smoker                                         10               10.64            3               3.85    5       7.04    0.131
  APOE4[†](#jdi12865-note-0004){ref-type="fn"}   19               20.21            7               8.97    7       9.86    0.059
  APOE3/3                                        64               68.09            54              69.23   41      57.75   0.458
  Drug use                                                                                                                 
  Aspirin                                        25               26.60            21              26.92   15      21.13   0.655
  Insulin                                        10               10.64            9               11.54   7       9.86    0.946
  Metformin                                      75               79.79            69              88.46   60      84.51   0.301
  Statin                                         49               52.13            45              57.69   40      56.34   0.744
  ACEI/ARB                                       57               60.64            50              64.10   39      54.93   0.505
  Female                                         18               19.15            36              46.15   41      57.75   \<0.001[\*](#jdi12865-note-0004){ref-type="fn"}
  Supplement group                               48               51.06            37              47.44   36      50.70   0.879

\*Comparison between the highest and lowest tertiles, *P* \< 0.05. ^†^One copy. ACEI, angiotensin‐converting enzyme inhibitor; albu:creat, albumin (g) and creatinine (μmol/L) ratio; ApoE, apolipoprotein E; ARB, angiotensin receptor blocker; DM, diabetes mellitus; GDS, Geriatric Depression Scale; HbA1c, glycosylated hemoglobin; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; max, maximum; MCI, mild cognitive impaired (Clinical Dementia Rating scale score 0.5); MCV, mean corpuscular volume; MMSE, Mini‐Mental State Examination; Non‐HDL, non‐high‐density lipoprotein; NTB, Neuropsychological Test Battery; SD, standard deviation; Total‐C, total cholesterol.
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Discussion {#jdi12865-sec-0009}
==========

The present study could not identify any clinical risk factor for global cognitive decline in older people with diabetes mellitus, except that lower serum HDL‐C was significantly associated with worse executive function after adjustments for confounders.

During the 27‐month observational period in this study, 15% of participants experienced cognitive decline. This contrasts with the 17% incidence in 1.6 years reported by Bruce *et al*.[11](#jdi12865-bib-0011){ref-type="ref"} This might be attributed to optimal diabetes control in this group of patients. Although the majority of participants had diabetes mellitus for \>10 years, most of them were treated with statin, metformin and angiotensin receptor blockers, which have been reported to be neuroprotective in people with diabetes mellitus[11](#jdi12865-bib-0011){ref-type="ref"}, [12](#jdi12865-bib-0012){ref-type="ref"}, [13](#jdi12865-bib-0013){ref-type="ref"}. In addition, the prevalence of diabetic complications was relatively low. One observational study in Japan reported that the existence of diabetic nephropathy, higher systolic blood pressure and higher serum triglycerides (or lower HDL‐C) were associated with cognitive decline after 6 years in participants with diabetes mellitus[14](#jdi12865-bib-0014){ref-type="ref"}. Another study found that a lower urinary albumin:creatinine ratio and use of angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers were protective for cognitive decline in older people with diabetes mellitus[11](#jdi12865-bib-0011){ref-type="ref"}.

Serum creatinine was higher in the decliners, but the difference was not independent of confounders. Renal dysfunction, as indicated by reduced creatinine clearance or higher urinary albumin:creatinine ratio, has been shown to be associated with cognitive decline in older people[15](#jdi12865-bib-0015){ref-type="ref"}. This might be attributed to a higher prevalence of cerebral small vessel disease[16](#jdi12865-bib-0016){ref-type="ref"}, which contributes to cognitive impairment[17](#jdi12865-bib-0017){ref-type="ref"}. The use of angiotensin‐converting enzyme inhibitor/angiotensin receptor blocker and metformin did not show a significant effect on cognitive impairment, which might be due to the frequent use of these drugs among all the participants. In addition, hypoglycemia is also a possible contributor of cognitive impairment in older people with diabetes mellitus[18](#jdi12865-bib-0018){ref-type="ref"}. However, serious hypoglycemia was rarely reported in the present study.

None of the clinical features were associated with global cognitive decline, but we found a robust association between HDL‐C and executive function. This suggests that serum HDL‐C is specifically associated with executive function in older people with diabetes mellitus. A case--control study found a positive association between HDL‐C levels and executive function in the diabetic statin users, but not in non‐users[19](#jdi12865-bib-0019){ref-type="ref"}. A longitudinal study in France reported that lower HDL‐C was associated with an increased risk of cognitive decline in executive function and psychomotor speed in older men[20](#jdi12865-bib-0020){ref-type="ref"}. In the present study, the association between HDL‐C and executive function was independent of sex and statin use in older people with diabetes mellitus.

It has been well demonstrated that HDL‐C undergoes significant qualitative changes in diabetes mellitus, in both structure and function[21](#jdi12865-bib-0021){ref-type="ref"}. When dealing with HDL‐C and cognitive function, we should keep in mind that cholesterol exists in two independent pools, the central nervous system and peripheral circulation. HDL‐C has multiple important functions in the brain. HDL‐C dysfunction in the central nervous system can directly cause cognitive impairment[22](#jdi12865-bib-0022){ref-type="ref"}. Although it is generally thought that there is no net transfer of cholesterol from the periphery into the central nervous system because of the blood--brain barrier, plasma HDL can affect the blood--brain barrier through its effects on endothelial function[23](#jdi12865-bib-0023){ref-type="ref"}. In addition, some small particles of HDL‐C; for example apolipoprotein A‐1, can cross blood--brain barrier. Furthermore, the major protein component of plasma HDL‐C, apolipoprotein A‐I, has a role in Aβ clearance[24](#jdi12865-bib-0024){ref-type="ref"}, and the anti‐oxidant and anti‐inflammatory properties of apolipoprotein A‐I/HDL‐C have been shown to play a significant role in neuroprotection[25](#jdi12865-bib-0025){ref-type="ref"}. Furthermore, the association between HDL‐C levels and cognition could be attributed to the higher cardiovascular risk associated with lower HDL‐C[26](#jdi12865-bib-0026){ref-type="ref"}.

Executive function is a primary domain of cognition that involves a broad set of cognitive abilities, such as attention, working memory, organization and persistence, which are essential to complex, goal‐directed activities[27](#jdi12865-bib-0027){ref-type="ref"}. Many studies have linked executive function with the pre‐frontal cortex[28](#jdi12865-bib-0028){ref-type="ref"}. Furthermore, white matter hyperintensities, irrespective of location, are associated with reduced frontal lobe metabolism and executive dysfunction. Previous studies have found that executive deficits could adversely affect glycemic control, and poor glycemic control in turn impairs cognitive function in adults with diabetes mellitus[29](#jdi12865-bib-0029){ref-type="ref"}. Hence, the preservation of executive function is important for the prevention of diabetic complications and global cognitive function in the longer term.

Serum HDL‐C can be increased by lifestyle modification. A meta‐analysis of 25 studies reported a mean net change in serum HDL‐C level of 2.53 mg/dL (95% confidence interval 1.36--3.70) with exercise averaging 3.7 sessions per week and 40.5 min per session[30](#jdi12865-bib-0030){ref-type="ref"}. Furthermore, several trials showed that exercise training programs improved the qualitative aspects of HDL‐C[31](#jdi12865-bib-0031){ref-type="ref"}, [32](#jdi12865-bib-0032){ref-type="ref"}, [33](#jdi12865-bib-0033){ref-type="ref"}. Polyunsaturated and monounsaturated fats, such as olive oil and coconut oil, mainly affect HDL~2~‐C or HDL~3~‐C concentration[34](#jdi12865-bib-0034){ref-type="ref"}, whereas very high polyunsaturated:saturated fat ratios and extremely high intakes of linoleic acid could significantly change serum HDL‐C levels[35](#jdi12865-bib-0035){ref-type="ref"}, [36](#jdi12865-bib-0036){ref-type="ref"}. In addition, studies of very low carbohydrate diets together with weight loss have shown a mean increase of 11% in serum HDL‐C level compared with low‐fat diets[37](#jdi12865-bib-0037){ref-type="ref"}. Overall, the dietary influence on serum HDL‐C level is therefore limited.

Nicotinic acid, statins, cholesteryl ester transfer protein inhibitors and fibrates are four classes of agents targeted at increasing HDL‐C levels[38](#jdi12865-bib-0038){ref-type="ref"}. Nicotinic acid and fibrates can reduce low‐density lipoprotein cholesterol by 5--25% and triglyceride by 20--50% simultaneously[39](#jdi12865-bib-0039){ref-type="ref"}, [40](#jdi12865-bib-0040){ref-type="ref"}. Cholesteryl ester transfer protein inhibitors can inhibit transferring of cholesterol esters from HDL‐C to larger lipoproteins, which could significantly increase HDL‐C levels and reduce low‐density lipoprotein cholesterol levels[41](#jdi12865-bib-0041){ref-type="ref"}.

Serum HDL‐C is a crude marker of HDL‐C function. Further studies on the influence of specific measures of HDL‐C function; for example, cholesterol efflux capacity of HDL‐C on cognitive function in older people with diabetes mellitus, are warranted.

The strengths of the present study included detailed neurocognitive assessments that tapped a range of cognitive domains at multiple time‐points, and the comprehensiveness of clinical factors. There were limitations. First, causality cannot be inferred, as it was an observational study. Second, the patients in the present study were the participants of a clinical trial. They might have been more health conscious than older people with diabetes mellitus in the general population. Third, we did not have data on diet and physical activity, which might confound the results.

In summary, no significant clinical factor for cognitive decline in older people with diabetes mellitus was found in the present study. Higher serum HDL‐C levels were associated with better performance in executive function. Elucidation of the underlying mechanisms of this association might lead to effective prevention strategies to prevent cognitive decline in older people with diabetes mellitus.
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